drug_type
RELEVANT_DRUG
intervention_type
Biological (autologous dendritic cell vaccine; cellular therapy)
drug_description
Autologous monocyte-derived dendritic cell (DC) vaccine pulsed with Epstein–Barr virus (EBV) antigens. Administered subcutaneously (5×10^6 cells/dose every 2 weeks for 3–5 doses) to present EBV peptides on MHC I/II and prime EBV-specific CD8+ and CD4+ T-cell responses in EBV+ nasopharyngeal carcinoma.
nci_thesaurus_concept_id
C200792
nci_thesaurus_definition
A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) pulsed with allogeneic Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell line (BLCL) lysate, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic EBV-transformed BLCL lysate. Upon re-administration of the allogeneic EBV-transformed BLCL lysate-pulsed autologous DC vaccine KSD-101, the immune system is exposed to EBV-specific antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against EBV-positive tumor cells or EBV-infected cells. This results in cell lysis and inhibition of cancer cell proliferation. EBV, a ubiquitous human herpes virus, is associated with various malignancies.
drug_mesh_term
Cancer Vaccines
drug_category
DC VACCINE
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Autologous monocyte-derived dendritic cells are pulsed with EBV antigens (BLCL lysate) ex vivo and reinfused subcutaneously, where they present EBV peptides on MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, driving CTL-mediated lysis of EBV-positive tumor cells (e.g., nasopharyngeal carcinoma).
drug_name
KSD-101
nct_id_drug_ref
NCT06370026